Aurinia Pharmaceuticals (AUPH) Competitors $9.03 -0.01 (-0.11%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends AUPH vs. TGTX, VKTX, TLX, BBIO, GRFS, CRNX, ALKS, AXSM, RARE, and BHVNShould you be buying Aurinia Pharmaceuticals stock or one of its competitors? The main competitors of Aurinia Pharmaceuticals include TG Therapeutics (TGTX), Viking Therapeutics (VKTX), Telix Pharmaceuticals Limited American Depositary Shares (TLX), BridgeBio Pharma (BBIO), Grifols (GRFS), Crinetics Pharmaceuticals (CRNX), Alkermes (ALKS), Axsome Therapeutics (AXSM), Ultragenyx Pharmaceutical (RARE), and Biohaven (BHVN). These companies are all part of the "pharmaceutical preparations" industry. Aurinia Pharmaceuticals vs. TG Therapeutics Viking Therapeutics Telix Pharmaceuticals Limited American Depositary Shares BridgeBio Pharma Grifols Crinetics Pharmaceuticals Alkermes Axsome Therapeutics Ultragenyx Pharmaceutical Biohaven Aurinia Pharmaceuticals (NASDAQ:AUPH) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, community ranking, media sentiment, dividends, profitability, valuation and risk. Which has preferable earnings & valuation, AUPH or TGTX? TG Therapeutics has higher revenue and earnings than Aurinia Pharmaceuticals. TG Therapeutics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAurinia Pharmaceuticals$220.36M5.87-$78.02M-$0.15-60.20TG Therapeutics$264.79M18.93$12.67M-$0.10-322.00 Does the MarketBeat Community believe in AUPH or TGTX? TG Therapeutics received 85 more outperform votes than Aurinia Pharmaceuticals when rated by MarketBeat users. Likewise, 76.57% of users gave TG Therapeutics an outperform vote while only 73.24% of users gave Aurinia Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAurinia PharmaceuticalsOutperform Votes57273.24% Underperform Votes20926.76% TG TherapeuticsOutperform Votes65776.57% Underperform Votes20123.43% Which has more risk and volatility, AUPH or TGTX? Aurinia Pharmaceuticals has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.25, meaning that its stock price is 125% more volatile than the S&P 500. Do analysts rate AUPH or TGTX? Aurinia Pharmaceuticals presently has a consensus price target of $10.00, indicating a potential upside of 10.74%. TG Therapeutics has a consensus price target of $40.67, indicating a potential upside of 26.29%. Given TG Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe TG Therapeutics is more favorable than Aurinia Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurinia Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75TG Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Is AUPH or TGTX more profitable? TG Therapeutics has a net margin of -5.42% compared to Aurinia Pharmaceuticals' net margin of -10.23%. Aurinia Pharmaceuticals' return on equity of -4.41% beat TG Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aurinia Pharmaceuticals-10.23% -4.41% -3.07% TG Therapeutics -5.42%-8.32%-3.40% Does the media favor AUPH or TGTX? In the previous week, TG Therapeutics had 1 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 4 mentions for TG Therapeutics and 3 mentions for Aurinia Pharmaceuticals. TG Therapeutics' average media sentiment score of 1.31 beat Aurinia Pharmaceuticals' score of 0.97 indicating that TG Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurinia Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in AUPH or TGTX? 36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 4.3% of Aurinia Pharmaceuticals shares are owned by company insiders. Comparatively, 10.5% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryTG Therapeutics beats Aurinia Pharmaceuticals on 15 of the 18 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Aurinia Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AUPH vs. The Competition Export to ExcelMetricAurinia PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.29B$6.57B$5.14B$9.08BDividend YieldN/A2.98%5.09%4.23%P/E Ratio-60.2010.5089.8217.18Price / Sales5.87195.801,116.21116.95Price / CashN/A57.1642.8937.86Price / Book3.435.094.784.78Net Income-$78.02M$151.83M$120.23M$225.60M7 Day Performance-3.63%-2.13%-1.92%-1.23%1 Month Performance2.96%-3.10%11.49%3.36%1 Year Performance-2.27%11.54%30.57%16.60% Aurinia Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AUPHAurinia Pharmaceuticals2.3312 of 5 stars$9.03-0.1%$10.00+10.7%+1.3%$1.29B$220.36M-60.20300TGTXTG Therapeutics4.3127 of 5 stars$34.75+8.5%$40.67+17.0%+87.1%$5.41B$233.66M-320.17290Positive NewsVKTXViking Therapeutics4.2931 of 5 stars$48.10+2.3%$106.75+121.9%+139.8%$5.36BN/A-51.5620Analyst ForecastGap UpTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$15.76+1.0%$21.00+33.2%N/A$5.28BN/A0.00N/ANews CoverageGap DownBBIOBridgeBio Pharma4.6974 of 5 stars$27.74+0.9%$47.69+71.9%-30.7%$5.24B$217.77M-11.63400Positive NewsGRFSGrifols3.4197 of 5 stars$7.61+3.8%N/A-28.0%$5.23B$7.01B0.0023,737Gap UpCRNXCrinetics Pharmaceuticals4.0778 of 5 stars$54.15+0.9%$70.82+30.8%+55.4%$5.02B$1.04M-14.39210Positive NewsALKSAlkermes4.6608 of 5 stars$30.45-0.2%$35.42+16.3%+9.3%$4.93B$1.51B15.652,100Positive NewsAXSMAxsome Therapeutics4.7638 of 5 stars$90.90+0.9%$125.93+38.5%+28.6%$4.41B$270.60M-13.80589Positive NewsRAREUltragenyx Pharmaceutical4.4444 of 5 stars$46.11+0.7%$87.46+89.7%-2.6%$4.26B$434.25M-7.081,276Analyst ForecastNews CoverageBHVNBiohaven3.7186 of 5 stars$40.94+6.4%$63.00+53.9%-4.4%$4.14B$462.51M-4.11239Analyst Forecast Related Companies and Tools Related Companies TGTX Alternatives VKTX Alternatives TLX Alternatives BBIO Alternatives GRFS Alternatives CRNX Alternatives ALKS Alternatives AXSM Alternatives RARE Alternatives BHVN Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AUPH) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aurinia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aurinia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
